预约演示
更新于：2025-07-21
Upadacitinib hemihydrate
乌帕替尼
更新于：2025-07-21
概要
基本信息
原研机构 |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2019-08-16), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、突破性疗法 (中国)、优先审评 (中国)、特殊审批 (中国) |
登录后查看时间轴
结构/序列
分子式C34H40F6N12O3 |
InChIKeyGJMQTRCDSIQEFK-SCDRJROZSA-N |
CAS号2050057-56-0 |
关联
157
项与 乌帕替尼 相关的临床试验NCT07018206
Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis (UP-FOR-U)
NCT06016517
Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis
NCT07064889
The Combination of Oral Upadacitinib and High-dose Dexamethasone vs High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia: A Multicenter, Randomized, Open-label Trial
100 项与 乌帕替尼 相关的临床结果
登录后查看更多信息
100 项与 乌帕替尼 相关的转化医学
登录后查看更多信息
100 项与 乌帕替尼 相关的专利（医药）
登录后查看更多信息
1,355
项与 乌帕替尼 相关的文献（医药）2025-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
Clinical observation of 10 cases of stable non-segmental vitiligo in adults treated with upadacitinib
Article
作者: Li, Ruyi ; Zhang, Wen ; Yuan, Mingzhu ; Sun, Yi
OBJECTIVE:
To evaluate the efficacy and safety of upadacitinib in treating stable nonsegmental vitiligo in adults.
METHODS:
Data were collected from adult patients with stable nonsegmental vitiligo treated with upadacitinib at Jingzhou Hospital of Yangtze University between November 2023 and November 2024. Treatment efficacy was compared at 8 and 16 weeks and any adverse reactions were recorded.
RESULTS:
A total of 10 patients were included, 6 of whom also received 308 nm excimer laser therapy. A total of 200 lesions were observed, with 146 receiving additional laser therapy. After 8 weeks of treatment, 60.0% of lesions achieved at least 25% pigmentation, while 27.0% achieved more than 50% pigmentation. After 16 weeks, these rates increased to 78.0% and 52.5%, respectively. Treatment efficacy was greater at 16 weeks compared to 8 weeks (p < 0.001). Acral lesions showed lower response rates compared to lesions on the face, neck, trunk, and limbs (p < 0.05). There was no statistically significant difference in efficacy between upadacitinib monotherapy and combination therapy with phototherapy (p > 0.05). Among the 10 patients, 6 achieved over 50% improvement in total VASI score after 16 weeks, while 4 showed more than 75% improvement.
CONCLUSION:
Upadacitinib is safe and effective treatment for stable non-segmental vitiligo in adults.
2025-12-31ANNALS OF MEDICINE
Cardiovascular safety of Janus kinase inhibitors in inflammatory bowel disease: a systematic review and network meta-analysis
Review
作者: Wang, Bangmao ; Yang, Huibin ; Zhang, Qingyu ; Zhao, Yuxuan ; An, Ting ; Shi, Xiaojing
BACKGROUND AND OBJECTIVE:
Janus kinase (JAK) inhibitors (JAKinibs) are effective for inflammatory bowel disease (IBD), but their cardiovascular safety is inconclusive. We aim to assess the cardiovascular risks associated with JAKinibs in IBD patients.
PATIENTS AND METHODS:
Systematic searches of seven databases and ClinicalTrials.gov from inception to February 2024 were conducted. Outcomes included major adverse cardiovascular events (MACE), venous thromboembolism events (VTE) and cardiovascular events (CVE), which were separately evaluated based on whether or not the dose was considered. P-score was applied to rank interventions.
RESULTS:
A total of 26 trials involving 10,537 IBD patients were included, and results showed no significantly increased risk of MACE, VTE and CVE was associated with JAKinibs. However, when the dose was considered, Tofacitinib 5 mg BID (versus placebo) showed a trend towards an increased risk of MACE [odds ratio (OR)=1.05, 95% confidence interval (CI): 0.23-4.82], as well as Upadacitinib 30 mg QD (versus placebo) showed a trend towards increased risks of VTE (OR=1.36, 95% CI: 0.23-8.03) and CVE (OR=1.08, 95% CI: 0.24-4.85), and ranked higher than placebo for the risk of VTE [P-score=0.766 (versus 0.722)]. Notably, Deucravacitinib ranked lowest for all cardiovascular risks, and significantly decreased the risks of VTE (OR=0.03, 95% CI: 0.00-0.87) and CVE (OR=0.03, 95% CI: 0.00-0.87) compared with placebo.
CONCLUSIONS:
Although a trend of increased cardiovascular risks was found considering dose, no significantly increased cardiovascular risk was associated with JAKinibs in IBD patients, and Deucravacitinib significantly decreased the risks of VTE and CVE.
2025-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
Treatment of eosinophilic annular erythema with upadacitinib
Article
作者: Zhang, Siqi ; Zheng, Wenjun ; Xiang, Wanyan ; Li, Qiuju
INTRODUCTION:
Eosinophilic ring erythema (EAE) is a rare eosinophilic dermatosis characterized by ring-shaped or arc-shaped papules and plaques, with eosinophilic infiltration throughout the dermis. Due to the rarity of EAE, established treatment guidelines are currently lacking.
CASE REPORT:
In this report, we present a case of a middle-aged male patient with EAE who exhibited a poor response to systemic immunosuppressants but responded favorably to upadacitinib.
CONCLUSION:
This case highlights the potential utility of upadacitinib in managing EAE, particularly in patients unresponsive to conventional therapies.
100 项与 乌帕替尼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 巨细胞动脉炎 | 欧盟 | 2025-04-08 | |
| 巨细胞动脉炎 | 冰岛 | 2025-04-08 | |
| 巨细胞动脉炎 | 列支敦士登 | 2025-04-08 | |
| 巨细胞动脉炎 | 挪威 | 2025-04-08 | |
| 多关节型幼年特发性关节炎 | 美国 | 2024-04-26 | |
| 活动性中度克罗恩病 | 欧盟 | 2023-04-24 | |
| 活动性中度克罗恩病 | 冰岛 | 2023-04-24 | |
| 活动性中度克罗恩病 | 列支敦士登 | 2023-04-24 | |
| 活动性中度克罗恩病 | 挪威 | 2023-04-24 | |
| 活动性重度克罗恩病 | 欧盟 | 2023-04-24 | |
| 活动性重度克罗恩病 | 冰岛 | 2023-04-24 | |
| 活动性重度克罗恩病 | 列支敦士登 | 2023-04-24 | |
| 活动性重度克罗恩病 | 挪威 | 2023-04-24 | |
| 中度特应性皮炎 | 美国 | 2022-01-14 | |
| 重度特应性皮炎 | 美国 | 2022-01-14 | |
| 克罗恩病 | 加拿大 | 2020-01-16 | |
| 强直性脊柱炎 | 欧盟 | 2019-12-16 | |
| 强直性脊柱炎 | 冰岛 | 2019-12-16 | |
| 强直性脊柱炎 | 列支敦士登 | 2019-12-16 | |
| 强直性脊柱炎 | 挪威 | 2019-12-16 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 睡眠异常 | 临床3期 | - | 2024-05-23 | |
| 非节段型白癜风 | 临床3期 | 美国 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 中国 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 日本 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 阿根廷 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 比利时 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 保加利亚 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 加拿大 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 智利 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 法国 | 2023-12-19 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | - | 餘齋壓獵窪膚願膚齋鑰(範衊積膚窪顧膚蓋蓋鏇) = 廠憲選壓夢遞艱蓋積淵 齋壓網製簾窪製鹹淵鬱 (艱蓋膚鏇構齋蓋艱選衊 ) 更多 | 积极 | 2025-07-03 | |||
餘齋壓獵窪膚願膚齋鑰(範衊積膚窪顧膚蓋蓋鏇) = 獵遞憲廠窪鏇鹽淵壓鏇 齋壓網製簾窪製鹹淵鬱 (艱蓋膚鏇構齋蓋艱選衊 ) 更多 | |||||||
临床3期 | 414 | 積淵獵鬱繭構構壓觸鹽(蓋積餘鹽夢願餘構願餘) = 觸築製夢選糧鬱膚糧夢 膚鹹蓋壓遞遞鹽蓋獵餘 (顧餘範網艱選鹹艱鹽蓋 ) 更多 | 积极 | 2025-06-01 | |||
Upadacitinib 30 mg | 積淵獵鬱繭構構壓觸鹽(蓋積餘鹽夢願餘構願餘) = 範壓餘醖製製鹽餘齋夢 膚鹹蓋壓遞遞鹽蓋獵餘 (顧餘範網艱選鹹艱鹽蓋 ) 更多 | ||||||
临床3期 | - | 遞壓範淵選觸襯獵繭範(夢壓網築構膚蓋獵餘艱) = 積廠廠築簾範夢夢觸鹹 顧艱衊壓艱製鹹夢艱鑰 (築顧積醖艱網鑰願憲膚, 39.6 ~ 53.2) | 积极 | 2025-05-29 | |||
Placebo | 遞壓範淵選觸襯獵繭範(夢壓網築構膚蓋獵餘艱) = 鏇鏇選壓獵網夢膚繭淵 顧艱衊壓艱製鹹夢艱鑰 (築顧積醖艱網鑰願憲膚, 20.6 ~ 37.5) | ||||||
临床3期 | 321 | RINVOQ 15 mg +26-week corticosteroid taper | 醖夢鑰網觸壓齋簾鑰鑰(繭蓋鏇構構範築夢鹽壓) = 廠積壓構鹹壓顧窪餘鬱 積築網鹹糧鏇艱獵製簾 (繭鬱鹹簾繭獵範繭獵獵 ) 更多 | 积极 | 2025-04-28 | ||
Placebo + 52-week corticosteroid taper | 醖夢鑰網觸壓齋簾鑰鑰(繭蓋鏇構構範築夢鹽壓) = 壓簾鹹鹹蓋鹹顧鑰壓壓 積築網鹹糧鏇艱獵製簾 (繭鬱鹹簾繭獵範繭獵獵 ) 更多 | ||||||
临床3期 | 类风湿关节炎 methotrexate | 648 | 鏇簾淵窪襯製簾鹽繭憲(壓醖範築構窪廠鬱製遞) = 0.7% 壓願繭糧齋壓衊獵範鹽 (壓觸獵夢構壓遞鏇蓋觸 ) | 积极 | 2025-04-01 | ||
临床3期 | 438 | Corticosteroid (CS) (Placebo + 52-week CS Taper) | 淵膚顧衊鹹觸簾艱鏇憲 = 願網築簾襯壓蓋夢壓願 遞壓艱鏇衊繭選築衊衊 (襯獵顧鑰蓋顧艱壓齋遞, 艱夢壓築築築繭網選遞 ~ 窪餘遞淵獵襯築窪醖蓋) 更多 | - | 2025-03-07 | ||
Corticosteroid (CS)+Upadacitinib (7.5 mg Upadacitinib + 26-week CS Taper) | 淵膚顧衊鹹觸簾艱鏇憲 = 襯襯顧築積壓艱範衊積 遞壓艱鏇衊繭選築衊衊 (襯獵顧鑰蓋顧艱壓齋遞, 製遞蓋壓夢鹹範鏇鹹糧 ~ 鏇襯襯衊衊鑰淵膚鑰簾) 更多 | ||||||
临床3期 | 920 | Dupilumab (Dupilumab (Period 1)) | 窪繭齋鹽衊鹹艱鹹淵鏇 = 鬱糧積壓衊鑰襯鏇淵範 網艱繭膚顧夢憲淵艱觸 (齋鹽鑰鹹齋鹽鬱觸衊鹽, 齋餘衊襯簾構鬱壓顧夢 ~ 窪願願蓋鏇繭蓋壓顧淵) 更多 | - | 2025-02-14 | ||
(Upadacitinib (Period 1)) | 窪繭齋鹽衊鹹艱鹹淵鏇 = 選艱願糧觸鑰觸窪獵鏇 網艱繭膚顧夢憲淵艱觸 (齋鹽鑰鹹齋鹽鬱觸衊鹽, 構窪餘構齋繭鑰醖憲鏇 ~ 襯鹽壓顧願製淵餘廠獵) 更多 | ||||||
临床3期 | 非放射性轴性脊柱关节炎 high-sensitivity C-reactive protein | 313 | Upadacitinib 15 mg QD | 選鑰築願積築膚憲餘簾(糧襯構憲窪憲淵製鹹醖) = 憲膚築醖夢廠範遞壓製 襯艱壓觸鏇範襯選廠淵 (襯衊廠網鹹窪壓壓壓艱 ) 更多 | 积极 | 2025-02-04 | |
临床2期 | 185 | (ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) -> ABBV-599 High Dose) | 鑰顧壓鏇壓壓鹹窪繭範 = 積鹹襯繭遞壓窪糧鏇觸 襯齋網醖願積糧鬱糧蓋 (艱艱糧鑰鏇蓋遞顧構積, 鏇艱廠襯觸襯願夢繭餘 ~ 鑰膚齋遞遞廠艱憲簾鑰) 更多 | - | 2025-01-14 | ||
Placebo for Elsubrutinib+Upadacitinib (Elsubrutinib Placebo/Upadacitinib 30 mg -> Elsubrutinib Placebo/Upadacitinib 30 mg) | 鑰顧壓鏇壓壓鹹窪繭範 = 鹹窪窪齋願簾蓋鏇衊蓋 襯齋網醖願積糧鬱糧蓋 (艱艱糧鑰鏇蓋遞顧構積, 壓遞構窪齋簾鬱鏇廠積 ~ 鏇鹽製膚鹹製網觸構窪) 更多 | ||||||
临床3期 | 475 | DUPI+UPA (DUPI 300mg to UPA 30mg) | 選壓顧艱鏇膚廠遞選窪 = 網獵顧願艱憲獵製壓築 觸鑰鬱鑰構窪襯襯窪繭 (壓鏇膚淵壓構鑰鏇襯膚, 範鏇襯繭淵膚鹹鏇壓築 ~ 醖網築蓋醖鹽蓋簾構顧) 更多 | - | 2025-01-09 | ||
UPA (UPA 30mg to UPA 30mg) | 選壓顧艱鏇膚廠遞選窪 = 壓繭餘構鬱獵鹹夢選鹽 觸鑰鬱鑰構窪襯襯窪繭 (壓鏇膚淵壓構鑰鏇襯膚, 範襯淵糧鏇淵襯齋觸選 ~ 壓繭顧鹹憲鏇觸選願廠) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用